NCCN Guidelines® Insights: Squamous Cell Skin Cancer, Version 1.2022

Featured Updates to the NCCN Guidelines

Authors:
Chrysalyne D. Schmults Dana-Farber/Brigham and Women’s Cancer Center;

Search for other papers by Chrysalyne D. Schmults in
Current site
Google Scholar
PubMed
Close
 MD, MS
,
Rachel Blitzblau Duke Cancer Institute;

Search for other papers by Rachel Blitzblau in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Sumaira Z. Aasi Stanford Cancer Institute;

Search for other papers by Sumaira Z. Aasi in
Current site
Google Scholar
PubMed
Close
 MD
,
Murad Alam Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

Search for other papers by Murad Alam in
Current site
Google Scholar
PubMed
Close
 MD
,
James S. Andersen City of Hope National Medical Center;

Search for other papers by James S. Andersen in
Current site
Google Scholar
PubMed
Close
 MD
,
Brian C. Baumann Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;

Search for other papers by Brian C. Baumann in
Current site
Google Scholar
PubMed
Close
 MD
,
Jeremy Bordeaux Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

Search for other papers by Jeremy Bordeaux in
Current site
Google Scholar
PubMed
Close
 MD, MPH
,
Pei-Ling Chen Moffitt Cancer Center;

Search for other papers by Pei-Ling Chen in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Robert Chin UCLA Jonsson Comprehensive Cancer Center;

Search for other papers by Robert Chin in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Carlo M. Contreras The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

Search for other papers by Carlo M. Contreras in
Current site
Google Scholar
PubMed
Close
 MD
,
Dominick DiMaio Fred & Pamela Buffett Cancer Center;

Search for other papers by Dominick DiMaio in
Current site
Google Scholar
PubMed
Close
 MD
,
Jessica M. Donigan Huntsman Cancer Institute at the University of Utah;

Search for other papers by Jessica M. Donigan in
Current site
Google Scholar
PubMed
Close
 MD
,
Jeffrey M. Farma Fox Chase Cancer Center;

Search for other papers by Jeffrey M. Farma in
Current site
Google Scholar
PubMed
Close
 MD
,
Karthik Ghosh Mayo Clinic Cancer Center;

Search for other papers by Karthik Ghosh in
Current site
Google Scholar
PubMed
Close
 MD
,
Roy C. Grekin UCSF Helen Diller Family Comprehensive Cancer Center;

Search for other papers by Roy C. Grekin in
Current site
Google Scholar
PubMed
Close
 MD
,
Kelly Harms University of Michigan Rogel Cancer Center;

Search for other papers by Kelly Harms in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Alan L. Ho Memorial Sloan Kettering Cancer Center;

Search for other papers by Alan L. Ho in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Ashley Holder O’Neal Comprehensive Cancer Center at UAB;

Search for other papers by Ashley Holder in
Current site
Google Scholar
PubMed
Close
 MD
,
John Nicholas Lukens Abramson Cancer Center at the University of Pennsylvania;

Search for other papers by John Nicholas Lukens in
Current site
Google Scholar
PubMed
Close
 MD
,
Theresa Medina University of Colorado Cancer Center;

Search for other papers by Theresa Medina in
Current site
Google Scholar
PubMed
Close
 MD
,
Kishwer S. Nehal Memorial Sloan Kettering Cancer Center;

Search for other papers by Kishwer S. Nehal in
Current site
Google Scholar
PubMed
Close
 MD
,
Paul Nghiem Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;

Search for other papers by Paul Nghiem in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Soo Park UC San Diego Moores Cancer Center;

Search for other papers by Soo Park in
Current site
Google Scholar
PubMed
Close
 MD
,
Tejesh Patel St. Jude Children’s Research Hospital/University of Tennessee Health Science Center;

Search for other papers by Tejesh Patel in
Current site
Google Scholar
PubMed
Close
 MD
,
Igor Puzanov Roswell Park Cancer Institute;

Search for other papers by Igor Puzanov in
Current site
Google Scholar
PubMed
Close
 MD, MSCI
,
Jeffrey Scott The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

Search for other papers by Jeffrey Scott in
Current site
Google Scholar
PubMed
Close
 MD, MHS
,
Aleksandar Sekulic Mayo Clinic Cancer Center;

Search for other papers by Aleksandar Sekulic in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Ashok R. Shaha Memorial Sloan Kettering Cancer Center;

Search for other papers by Ashok R. Shaha in
Current site
Google Scholar
PubMed
Close
 MD
,
Divya Srivastava UT Southwestern Simmons Comprehensive Cancer Center;

Search for other papers by Divya Srivastava in
Current site
Google Scholar
PubMed
Close
 MD
,
William Stebbins Vanderbilt-Ingram Cancer Center;

Search for other papers by William Stebbins in
Current site
Google Scholar
PubMed
Close
 MD
,
Valencia Thomas The University of Texas MD Anderson Cancer Center;

Search for other papers by Valencia Thomas in
Current site
Google Scholar
PubMed
Close
 MD
,
Yaohui G. Xu University of Wisconsin Carbone Cancer Center; and

Search for other papers by Yaohui G. Xu in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Beth McCullough National Comprehensive Cancer Network.

Search for other papers by Beth McCullough in
Current site
Google Scholar
PubMed
Close
 RN, BS, CMSRN
,
Mary A. Dwyer National Comprehensive Cancer Network.

Search for other papers by Mary A. Dwyer in
Current site
Google Scholar
PubMed
Close
 MS, CGC
, and
Mai Q. Nguyen National Comprehensive Cancer Network.

Search for other papers by Mai Q. Nguyen in
Current site
Google Scholar
PubMed
Close
 PhD
Restricted access

The NCCN Guidelines for Squamous Cell Skin Cancer provide recommendations for diagnostic workup, clinical stage, and treatment options for patients with cutaneous squamous cell carcinoma. The NCCN panel meets annually to discuss updates to the guidelines based on comments from panel members and the Institutional Review, as well as submissions from within NCCN and external organizations. These NCCN Guidelines Insights focus on the introduction of a new surgical recommendation terminology (peripheral and deep en face margin assessment), as well as recent updates on topical prophylaxis, immunotherapy for regional and metastatic disease, and radiation therapy.

  • Collapse
  • Expand
  • 1.

    Rubió-Casadevall J, Hernandez-Pujol AM, Ferreira-Santos MC, et al. Trends in incidence and survival analysis in non-melanoma skin cancer from 1994 to 2012 in Girona, Spain: a population-based study. Cancer Epidemiol 2016;45:610.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Sella T, Goren I, Shalev V, et al. Incidence trends of keratinocytic skin cancers and melanoma in Israel 2006-11. Br J Dermatol 2015;172:202207.

  • 3.

    Rudolph C, Schnoor M, Eisemann N, et al. Incidence trends of nonmelanoma skin cancer in Germany from 1998 to 2010. J Dtsch Dermatol Ges 2015;13:788797.

  • 4.

    Goon PK, Greenberg DC, Igali L, et al. Squamous cell carcinoma of the skin has more than doubled over the last decade in the UK. Acta Derm Venereol 2016;96:820821.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Robsahm TE, Helsing P, Veierød MB. Cutaneous squamous cell carcinoma in Norway 1963-2011: increasing incidence and stable mortality. Cancer Med 2015;4:472480.

  • 6.

    Rogers HW, Weinstock MA, Feldman SR, et al. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012. JAMA Dermatol 2015;151:10811086.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Perera E, Gnaneswaran N, Staines C, et al. Incidence and prevalence of non-melanoma skin cancer in Australia: a systematic review. Australas J Dermatol 2015;56:258267.

  • 8.

    Schmults CD, Karia PS, Carter JB, et al. Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study. JAMA Dermatol 2013;149:541547.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Eisemann N, Jansen L, Castro FA, et al. Survival with nonmelanoma skin cancer in Germany. Br J Dermatol 2016;174:778785.

  • 10.

    Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol 1992;26:976990.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Turner RJ, Leonard N, Malcolm AJ, et al. A retrospective study of outcome of Mohs’ micrographic surgery for cutaneous squamous cell carcinoma using formalin fixed sections. Br J Dermatol 2000;142:752757.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Malhotra R, Huilgol SC, Huynh NT, et al. The Australian Mohs database: periocular squamous cell carcinoma. Ophthalmology 2004;111:617623.

  • 13.

    Leibovitch I, Huilgol SC, Selva D, et al. Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia I. Experience over 10 years. J Am Acad Dermatol 2005;53:253260.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Leibovitch I, Huilgol SC, Richards S, et al. Scalp tumors treated with Mohs micrographic surgery: clinical features and surgical outcome. Dermatol Surg 2006;32:13691374.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Silapunt S, Peterson SR, Goldberg LH. Squamous cell carcinoma of the auricle and Mohs micrographic surgery. Dermatol Surg 2005;31:14231427.

  • 16.

    van der Eerden PA, Prins ME, Lohuis PJ, et al. Eighteen years of experience in Mohs micrographic surgery and conventional excision for nonmelanoma skin cancer treated by a single facial plastic surgeon and pathologist. Laryngoscope 2010;120:23782384.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Pugliano-Mauro M, Goldman G. Mohs surgery is effective for high-risk cutaneous squamous cell carcinoma. Dermatol Surg 2010;36:15441553.

  • 18.

    Skaria AM. Recurrence of basosquamous carcinoma after Mohs micrographic surgery. Dermatology 2010;221:352355.

  • 19.

    Breuninger H, Schaumburg-Lever G. Control of excisional margins by conventional histopathological techniques in the treatment of skin tumours. An alternative to Mohs’ technique. J Pathol 1988;154:167171.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Vuyk HD, Lohuis PJ. Mohs micrographic surgery for facial skin cancer. Clin Otolaryngol Allied Sci 2001;26:265273.

  • 21.

    Mourouzis C, Boynton A, Grant J, et al. Cutaneous head and neck SCCs and risk of nodal metastasis – UK experience. J Craniomaxillofac Surg 2009;37:443447.

  • 22.

    Cherpelis BS, Marcusen C, Lang PG. Prognostic factors for metastasis in squamous cell carcinoma of the skin. Dermatol Surg 2002;28:268273.

  • 23.

    Lawrence N, Cottel WI. Squamous cell carcinoma of skin with perineural invasion. J Am Acad Dermatol 1994;31:3033.

  • 24.

    Leibovitch I, Huilgol SC, Selva D, et al. Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia II. Perineural invasion. J Am Acad Dermatol 2005;53:261266.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Lin C, Tripcony L, Keller J, et al. Perineural infiltration of cutaneous squamous cell carcinoma and basal cell carcinoma without clinical features. Int J Radiat Oncol Biol Phys 2012;82:334340.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Kropp L, Balamucki CJ, Morris CG, et al. Mohs resection and postoperative radiotherapy for head and neck cancers with incidental perineural invasion. Am J Otolaryngol 2013;34:373377.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Ruiz ES, Koyfman SA, Que SKT, et al. Evaluation of the utility of localized adjuvant radiation for node-negative primary cutaneous squamous cell carcinoma with clear histologic margins. J Am Acad Dermatol 2020;82:420429.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Miller J, Chang T, Schwartz D, et al. Outcomes of adjuvant radiotherapy following negative surgical margins for cutaneous squamous cell carcinoma. Dermatol Surg 2019;45:11111116.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Brodland DG, Zitelli JA. Surgical margins for excision of primary cutaneous squamous cell carcinoma. J Am Acad Dermatol 1992;27:241248.

  • 30.

    Schell AE, Russell MA, Park SS. Suggested excisional margins for cutaneous malignant lesions based on Mohs micrographic surgery. JAMA Facial Plast Surg 2013;15:337343.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Batra RS, Kelley LC. Predictors of extensive subclinical spread in nonmelanoma skin cancer treated with Mohs micrographic surgery. Arch Dermatol 2002;138:10431051.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Stratigos AJ, Garbe C, Dessinioti C, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. Epidemiology, diagnostics and prevention. Eur J Cancer 2020;128:6082.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Stratigos AJ, Garbe C, Dessinioti C, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. Eur J Cancer 2020;128:83102.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Keohane SG, Botting J, Budny PG, et al. British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma 2020. Br J Dermatol 2021;184:401414.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35.

    Newlands C, Currie R, Memon A, et al. Non-melanoma skin cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol 2016;130(Suppl 2):S125132.

  • 36.

    Jorizzo J, Weiss J, Furst K, et al. Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: a randomized, vehicle-controlled clinical trial. Arch Dermatol 2004;140:813816.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Stockfleth E, von Kiedrowski R, Dominicus R, et al. Efficacy and safety of 5-fluorouracil 0.5%/salicylic acid 10% in the field-directed treatment of actinic keratosis: a phase III, randomized, double-blind, vehicle-controlled trial. Dermatol Ther (Heidelb) 2017;7:8196.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    Pomerantz H, Hogan D, Eilers D, et al. Long-term efficacy of topical fluorouracil cream, 5%, for treating actinic keratosis: a randomized clinical trial. JAMA Dermatol 2015;151:952960.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Rahvar M, Lamel SA, Maibach HI. Randomized, vehicle-controlled trials of topical 5-fluorouracil therapy for actinic keratosis treatment: an overview. Immunotherapy 2012;4:939945.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Stockfleth E, Zwingers T, Willers C. Recurrence rates and patient assessed outcomes of 0.5% 5-fluorouracil in combination with salicylic acid treating actinic keratoses. Eur J Dermatol 2012;22:370374.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Cunningham TJ, Tabacchi M, Eliane JP, et al. Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. J Clin Invest 2017;127:106116.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Hadley G, Derry S, Moore RA. Imiquimod for actinic keratosis: systematic review and meta-analysis. J Invest Dermatol 2006;126:12511255.

  • 43.

    Gebauer K, Shumack S, Cowen PS. Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial. Br J Dermatol 2009;161:897903.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    Swanson N, Smith CC, Kaur M, et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3, multicenter, randomized, double-blind, placebo-controlled studies. J Drugs Dermatol 2014;13:166169.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45.

    Alomar A, Stockfleth E, Dirschka T, et al. Efficacy and safety of imiquimod 3.75% from Lmax in actinic keratosis according to Fitzpatrick skin type. J Drugs Dermatol 2016;15:285289.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 46.

    Blauvelt A, Kempers S, Lain E, et al. Phase 3 trials of tirbanibulin ointment for actinic keratosis. N Engl J Med 2021;384:512520.

  • 47.

    Freeman M, Vinciullo C, Francis D, et al. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatolog Treat 2003;14:99106.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 48.

    Piacquadio DJ, Chen DM, Farber HF, et al. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials. Arch Dermatol 2004;140:4146.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49.

    Hauschild A, Stockfleth E, Popp G, et al. Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studies. Br J Dermatol 2009;160:10661074.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    Szeimies RM, Matheson RT, Davis SA, et al. Topical methyl aminolevulinate photodynamic therapy using red light-emitting diode light for multiple actinic keratoses: a randomized study. Dermatol Surg 2009;35:586592.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51.

    Szeimies RM, Radny P, Sebastian M, et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study. Br J Dermatol 2010;163:386394.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52.

    Szeimies RM, Stockfleth E, Popp G, et al. Long-term follow-up of photodynamic therapy with a self-adhesive 5-aminolaevulinic acid patch: 12 months data. Br J Dermatol 2010;162:410414.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Dirschka T, Radny P, Dominicus R, et al. Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis. Br J Dermatol 2013;168:825836.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54.

    Pariser DM, Houlihan A, Ferdon MB, et al. Randomized vehicle-controlled study of short drug incubation aminolevulinic acid photodynamic therapy for actinic keratoses of the face or scalp. Dermatol Surg 2016;42:296304.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 55.

    Jansen MHE, Kessels JPHM, Nelemans PJ, et al. Randomized trial of four treatment approaches for actinic keratosis. N Engl J Med 2019;380:935946.

  • 56.

    Rosenberg AR, Tabacchi M, Ngo KH, et al. Skin cancer precursor immunotherapy for squamous cell carcinoma prevention. JCI Insight 2019;4:4.

  • 57.

    Shuttleworth D, Marks R, Griffin PJ, et al. Treatment of cutaneous neoplasia with etretinate in renal transplant recipients. Q J Med 1988;68:717725.

  • 58.

    Bavinck JN, Tieben LM, Van der Woude FJ, et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol 1995;13:19331938.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 59.

    Gibson GE, O’Grady A, Kay EW, et al. Low-dose retinoid therapy for chemoprophylaxis of skin cancer in renal transplant recipients. J Eur Acad Dermatol Venereol 1998;10:4247.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60.

    McKenna DB, Murphy GM. Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low-dose acitretin. Br J Dermatol 1999;140:656660.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 61.

    George R, Weightman W, Russ GR, et al. Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients. Australas J Dermatol 2002;43:269273.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 62.

    de Sévaux RG, Smit JV, de Jong EM, et al. Acitretin treatment of premalignant and malignant skin disorders in renal transplant recipients: clinical effects of a randomized trial comparing two doses of acitretin. J Am Acad Dermatol 2003;49:407412.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 63.

    Kraemer KH, DiGiovanna JJ, Moshell AN, et al. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1988;318:16331637.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 64.

    Nijsten TE, Stern RS. Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study. J Am Acad Dermatol 2003;49:644650.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 65.

    Badri O, Schmults CD, Karia PS, et al. Efficacy and cost analysis for acitretin for basal and squamous cell carcinoma prophylaxis in renal transplant recipients. Dermatol Surg 2021;47:125126.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 66.

    Holoye PY, Byers RM, Gard DA, et al. Combination chemotherapy of head and neck cancer. Cancer 1978;42:16611669.

  • 67.

    Sadek H, Azli N, Wendling JL, et al. Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin. Cancer 1990;66:16921696.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 68.

    Khansur T, Kennedy A. Cisplatin and 5-fluorouracil for advanced locoregional and metastatic squamous cell carcinoma of the skin. Cancer 1991;67:20302032.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 69.

    Cartei G, Cartei F, Interlandi G, et al. Oral 5-fluorouracil in squamous cell carcinoma of the skin in the aged. Am J Clin Oncol 2000;23:181184.

  • 70.

    Shin DM, Glisson BS, Khuri FR, et al. Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol 2002;20:364370.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 71.

    Nakamura K, Okuyama R, Saida T, et al. Platinum and anthracycline therapy for advanced cutaneous squamous cell carcinoma. Int J Clin Oncol 2013;18:506509.

  • 72.

    McDowell LJ, Tan TJ, Bressel M, et al. Outcomes of cutaneous squamous cell carcinoma of the head and neck with parotid metastases. J Med Imaging Radiat Oncol 2016;60:668676.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 73.

    Nottage MK, Lin C, Hughes BG, et al. Prospective study of definitive chemoradiation in locally or regionally advanced squamous cell carcinoma of the skin. Head Neck 2017;39:679683.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 74.

    Amoils M, Lee CS, Sunwoo J, et al. Node-positive cutaneous squamous cell carcinoma of the head and neck: Survival, high-risk features, and adjuvant chemoradiotherapy outcomes. Head Neck 2017;39:881885.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 75.

    Tanvetyanon T, Padhya T, McCaffrey J, et al. Postoperative concurrent chemotherapy and radiotherapy for high-risk cutaneous squamous cell carcinoma of the head and neck. Head Neck 2015;37:840845.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 76.

    Jarkowski A III, Hare R, Loud P, et al. Systemic therapy in advanced cutaneous squamous cell carcinoma (CSCC): the Roswell Park experience and a review of the literature. Am J Clin Oncol 2016;39:545548.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 77.

    Suntharalingam M, Haas ML, Conley BA, et al. The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 2000;47:4956.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 78.

    Vlacich G, Diaz R, Thorpe SW, et al. Intensity-modulated radiation therapy with concurrent carboplatin and paclitaxel for locally advanced head and neck cancer: toxicities and efficacy. Oncologist 2012;17:673681.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 79.

    Maring S, Elsayad K, Stenner M, et al. Efficacy of carboplatin/paclitaxel-based radiochemotherapy in locally advanced squamous cell carcinoma of head and neck. Oncol Res Treat 2018;41:736743.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 80.

    Agulnik M, Rhee EN, Yao M, et al. Paclitaxel, carboplatin, and concomitant radiotherapy for resected patients with high risk head and neck cancer. J Chemother 2005;17:237241.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 81.

    Bossi P, Cavalieri S, Perrone F, et al. Efficacy and safety of single agent pan-HER inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer (sSCC) [abstract]. J Clin Oncol 2017;35(Suppl):Abstract 9543.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 82.

    National Institutes of Health. Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia. Available at: https://clinicaltrials.gov/ct2/show/record/NCT00563290. Accessed Aug 28, 2017.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 83.

    National Institutes of Health. Efficacy and Safety of Dacomitinib in the Treatment of Skin Squamous Cell Cancer. Available at: https://clinicaltrials.gov/ct2/show/record/NCT02268747. Accessed Aug 28, 2017.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 84.

    National Institutes of Health. Study of Erlotinib in the Treatment of Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC) of the Skin. Available at: https://clinicaltrials.gov/ct2/show/record/NCT01198028. Accessed Aug 28, 2017.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 85.

    Maubec E, Helfen S, Scheer-Senyarich I, et al. CARSKIN: pembrolizumab as first line therapy in patients with unresectable cutaneous squamous cell carcinoma (cSCC) [abstract]. J Clin Oncol 2017;35(Suppl):Abstract TPS9596.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 86.

    Papadopoulos KP, Owonikoko TK, Johnson ML, et al. REGN2810: a fully human anti-PD-1 monoclonal antibody, for patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC)—initial safety and efficacy from expansion cohorts (ECs) of phase I study [abstract]. J Clin Oncol 2017;35(Suppl):Abstract 9503.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 87.

    Migden MR, Khushalani NI, Chang ALS, et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol 2020;21:294305.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 88.

    Migden MR, Rischin D, Schmults CD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med 2018;379:341351.

  • 89.

    Rischin D, Khushalani NI, Schmults CD, et al. Phase II study of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC): longer follow-up [abstract]. J Clin Oncol 2020;38(Suppl):Abstract 10018.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 90.

    Rischin D, Migden MR, Lim AM, et al. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. J Immunother Cancer 2020;8:8.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 91.

    Hughes BGM, Munoz-Couselo E, Mortier L, et al. Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial. Ann Oncol 2021;32:12761285.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 92.

    Grob JJ, Gonzalez R, Basset-Seguin N, et al. Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase II trial (KEYNOTE-629). J Clin Oncol 2020;38:29162925.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 93.

    Abbatucci JS, Boulier N, Laforge T, et al. Radiation therapy of skin carcinomas: results of a hypofractionated irradiation schedule in 675 cases followed more than 2 years. Radiother Oncol 1989;14:113119.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 94.

    Kwan W, Wilson D, Moravan V. Radiotherapy for locally advanced basal cell and squamous cell carcinomas of the skin. Int J Radiat Oncol Biol Phys 2004;60:406411.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 95.

    Hernández-Machin B, Borrego L, Gil-García M, et al. Office-based radiation therapy for cutaneous carcinoma: evaluation of 710 treatments. Int J Dermatol 2007;46:453459.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 96.

    Barysch MJ, Eggmann N, Beyeler M, et al. Long-term recurrence rate of large and difficult to treat cutaneous squamous cell carcinomas after superficial radiotherapy. Dermatology 2012;224:5965.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 97.

    Cognetta AB, Howard BM, Heaton HP, et al. Superficial x-ray in the treatment of basal and squamous cell carcinomas: a viable option in select patients. J Am Acad Dermatol 2012;67:12351241.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 98.

    Schulte KW, Lippold A, Auras C, et al. Soft x-ray therapy for cutaneous basal cell and squamous cell carcinomas. J Am Acad Dermatol 2005;53:9931001.

  • 99.

    Lovett RD, Perez CA, Shapiro SJ, et al. External irradiation of epithelial skin cancer. Int J Radiat Oncol Biol Phys 1990;19:235242.

  • 100.

    Baris G, Visser AG, van Andel JG. The treatment of squamous cell carcinoma of the nasal vestibule with interstitial iridium implantation. Radiother Oncol 1985;4:121125.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 101.

    Crook JM, Mazeron JJ, Marinello G, et al. Interstitial iridium 192 for cutaneous carcinoma of the external nose. Int J Radiat Oncol Biol Phys 1990;18:243248.

  • 102.

    McCollough WM, Mendenhall NP, Parsons JT, et al. Radiotherapy alone for squamous cell carcinoma of the nasal vestibule: management of the primary site and regional lymphatics. Int J Radiat Oncol Biol Phys 1993;26:7379.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 103.

    Mendenhall NP, Parsons JT, Cassisi NJ, et al. Carcinoma of the nasal vestibule. Int J Radiat Oncol Biol Phys 1984;10:627637.

  • 104.

    Guix B, Finestres F, Tello J, et al. Treatment of skin carcinomas of the face by high-dose-rate brachytherapy and custom-made surface molds. Int J Radiat Oncol Biol Phys 2000;47:95102.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 105.

    Mazeron JJ, Chassagne D, Crook J, et al. Radiation therapy of carcinomas of the skin of nose and nasal vestibule: a report of 1676 cases by the Groupe Europeen de Curiethérapie. Radiother Oncol 1988;13:165173.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 106.

    Mazeron JJ, Ghalie R, Zeller J, et al. Radiation therapy for carcinoma of the pinna using iridium 192 wires: a series of 70 patients. Int J Radiat Oncol Biol Phys 1986;12:17571763.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 21223 9319 776
PDF Downloads 17646 8084 670
EPUB Downloads 0 0 0